Cairo – Mubasher: Kahira Pharmaceuticals posted a 22.47% year-on-year (YoY) increase in profits after tax during the first half (H1) of fiscal year (FY) 2021/2022.
Net profits amounted to EGP 82.05 million in the six-month period that ended on 31 December 2021, versus EGP 67 million in the same period of 2020, according to a bourse filing.
Revenues declined to EGP 527.10 million in H1-21/22, down by 0.96% from EGP 532.23 million in the same period a year earlier.
